Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2010

View Archived Issues

Pharmasset selects anti-HCV purine nucleotide prodrugs to develop

Yissum claims new MMP-2 inhibitors

Early control of blood pressure achieved by telmisartan/nifedipine GIST, TALENT data suggest

MyD88 inhibitor STJJ induces tolerance of skin transplants in mice

Metformin has beneficial effects in patients with chronic heart failure

Phase II and III trials examine SIR-Spheres in patients with refractory colorectal liver metastases

STX-100 receives FDA orphan drug designation for IPF

Glenmark discovers novel TRPA1 receptor antagonist GRC-17536

FDA grants orphan drug designation to BMN-701 for Pompe's disease

New GHS-R antagonists claimed by sanofi-aventis

Celgene discovers new isotopologues of lenalidomide

New GlyT-1 inhibitors identified by sanofi-aventis

Janssen presents novel antibacterial agents

BTG to receive marketing rights for Nycomed's CroFab and DigiFab

Health Canada approves Sativex for spasticity due to MS

FDA approves Suboxone sublingual film

Meda to acquire specialty pharmaceutical company, Alaven

Pluristem's PLX cells included in diastolic heart failure program

Treatment with MP4OX effective in severe trauma patients

Positive outcome to decentralized procedure for European approval of Twinject

PEARL-HF study shows reduced hyperkalemia with RLY-5016

FDA approves Lumigan 0.01% for reducing IOP in glaucoma patients

ImmuneRegen to submit proposal for funding Homspera development

Otonomy closes Series B financing

Neurotech initiates phase I AAD-2004 trial targeting AD, PD and ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...